@article{199a7fac781b4498bffefd56816cad75,
title = "The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis",
abstract = "Objective: Processing speed (PS) deficits are the most common cognitive deficits in multiple sclerosis (MS), followed by learning and memory deficits, and are often an early cognitive problem. It has been argued that impaired PS is a primary consequence of MS, which in turn decreases learning. The current analysis examined the association between PS and learning in a large cohort of individuals with progressive MS. Methods: Baseline data from a randomized clinical trial on rehabilitation taking place at 11 centers across North America and Europe were analyzed. Participants included 275 individuals with clinically definite progressive MS (primary, secondary) consented into the trial. Results: Symbol Digit Modalities Test (SDMT) significantly correlated with California Verbal Learning Test-II (CVLT-II) (r = 0.21, p = 0.0003) and Brief Visuospatial Memory Test–Revised (BVMT-R) (r = 0.516, p < 0.0001). Receiver operating characteristic (ROC) analysis of the SDMT z score to distinguish between impaired and non-impaired CVLT-II performance demonstrated an area under the curve (AUC) of 0.61 (95% confidence interval (CI): 0.55–0.68) and a threshold of −1.62. ROC analysis between SDMT and BVMT-R resulted in an AUC of 0.77 (95% CI: 0.71–0.83) and threshold of −1.75 for the SDMT z score to predict impaired BVMT-R. Conclusion: Results indicate little ability beyond chance to predict CVLT-II from SDMT (61%), albeit statistically significant. In contrast, there was a 77% chance that the model could distinguish between impaired and non-impaired BVMT-R. Several potential explanations are discussed.",
keywords = "BICAMS, Progressive multiple sclerosis, SDMT, cognition, memory, processing speed",
author = "Chiaravalloti, {Nancy D.} and John DeLuca and Amber Salter and Amato, {Maria Pia} and Giampaolo Brichetto and Jeremy Chataway and Ulrik Dalgas and Rachel Farrell and Peter Feys and Massimo Filippi and Jennifer Freeman and Matilde Inglese and Cecilia Meza and Moore, {Nancy B.} and Motl, {Robert W.} and Rocca, {Maria Assunta} and Sandroff, {Brian M.} and Gary Cutter and Anthony Feinstein",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: N.D.C. is on an Advisory Board for Akili Interactive and is a member of the Editorial Boards of Multiple Sclerosis Journal and Frontiers in NeuroTrauma. M.P.A. received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Roche, Pharmaceutical Industries, and Fondazione Italiana Sclerosi Multiplav. G.B. has no disclosures to report. J.C. has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for commercial trials funded by Actelion, Biogen, Novartis, and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards/consultancy for Azadyne, Biogen, Celgene, MedDay, Merck, and Roche. U.D. has received research support, travel grants, and/or teaching honorary from Biogen Idec, Merck-Serono, Novartis, Bayer Schering, and Sanofi-Aventis as well as honoraria from serving on scientific advisory boards of Biogen Idec and Genzyme. J.D. is an Associate Editor of the Archives of Physical Medicine and Rehabilitation, and Neuropsychology Review; received compensation for consulting services and/or speaking activities from Biogen Idec, Celgene, MedRhythms, and Novartis; and receives research support from Biogen Idec, National Multiple Sclerosis Society, Consortium of Multiple Sclerosis Centers, and National Institutes of Health. C.M. has no disclosures to report. N.B.M. has no disclosures to report. R.F. has received honoraria and served on advisory panels for Merck, TEVA, Novartis, Genzyme, GW Pharma (Jazz Pharmaceuticals), Allergan, Merz, Ipsen, and Biogen. She is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. P.F. is editorial board member of NNR and MSJ, provides consultancy to NeuroCompass, and was board of advisory board meetings for BIOGEN. M.F. is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). J.F. has been awarded research grants from the NIHR, UK. M.I. is Co-Editor for Controversies for Multiple Sclerosis Journal; received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme; and received research support from NIH, NMSS Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla. R.W.M. has no disclosures to report. M.A.R. received speaker honoraria from Biogen Idec, Novartis, Teva Neurosciences, Merck-Serono, Genzyme, Roche, Bayer and Celgene and receives research support from the Canadian MS Society and Fondazione Italiana Sclerosi Multipla. B.S. has no disclosures to report. A.S. serves on the Data Safety Monitoring Board for National Institutes of Health and PCORI studies, is a member of the Neurology editorial board, and receives research grants from the Department of Defense, MS Society of Canada, National MS Society and the Consortium of MS Centers. G.C. is a member of Data and Safety Monitoring Boards for AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Green Valley Pharma, Immunic, Mapi Pharmaceuticals LTD, Merck, Merck/Pfizer, Mitsubishi Tanabe Pharma Holdings, Opko Biologics, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, Teva Pharmaceuticals, VielaBio Inc,, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee). Alexion, Antisense Therapeutics, Biogen, Clinical Trial Solutions LLC, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune/Viela Bio/Horizon Pharmaceuticals, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Protalix Biotherapeutics, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche. G.C. is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc., a private consulting company located in Birmingham AL. A.F. is on an Advisory Board for Akili Interactive and reports grants from the MS Society of Canada, book royalties from Johns Hopkins University Press, Cambridge University Press, Amadeus Press, and Glitterati Editions, and speaker{\textquoteright}s honoraria from Novartis, Biogen, Roche, and Sanofi Genzyme. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by the MS Society of Canada (grant # EGID3185). Publisher Copyright: {\textcopyright} The Author(s), 2022.",
year = "2022",
month = oct,
doi = "10.1177/13524585221088190",
language = "English",
volume = "28",
pages = "1783--1792",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "11",
}